The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers
Turan et al.,
The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in..,
The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2022.102328
Retrospective 237 low-risk healthcare workers in Turkey, 123 treated with favipiravir and 114 treated with HCQ, showing lower hospitalization and faster viral clearance with favipiravir, and similar improvement. This study is subject to substantial
confounding by time because the patients in each group are from different time periods with an overall period of 10 months including the beginning of the pandemic, resulting in significant differences in variants encountered and SOC. Propensity for hospital admission may also have changed significantly.
This study is excluded in meta
analysis:
substantial
confounding by time likely due to separation of groups in different time periods over an extended period of time.
risk of hospitalization, 79.4% lower, RR 0.21, p = 0.001, treatment 4 of 123 (3.3%), control 18 of 114 (15.8%), NNT 8.0.
|
recovery time, 11.0% higher, relative time 1.11, p = 0.51, treatment 123, control 114.
|
time to viral-, 21.6% lower, relative time 0.78, p < 0.001, treatment 123, control 114.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Turan et al., 1 Feb 2022, retrospective, Turkey, peer-reviewed, mean age 33.4, 10 authors, study period 11 March, 2020 - 1 January, 2021, this trial compares with another treatment - results may be better when compared to placebo.
Abstract: ARTICLE IN PRESS
braz j infect dis. 2022;xxx(xx):102328
The Brazilian Journal of
INFECTIOUS DISEASES
w w w. e l s e v i e r. c o m / l o c a t e / b j i d
Original Article
The effect of favipiravir versus hydroxychloroquine on
clinical and laboratory findings in COVID-19 in healthcare
Q1 workers X X
Q2
b
€
1X XDerya
XD
Bay{rl{ Turan a,
D2X X *, D3X XMehtap Menteş bD4X X , D5X XY{ld{ran Ozel
D6X X ,
c
_
an cD10X X , D1X XNeşe Ibil
du
lu aD8X X , D9X XBurcu Aydog
€ sun Gu
€ neşdog
D12X X , D13X XFu
D7X XK{vanç Şerefhanog
e
e
f
€ neyt Saltu
€ rk D18X X , D19X XHakan Çelik D20X X
D15X XHijran Mammadova Orucova D16X X , D17X XCu
d
D14X X ,
€ zy{l University Faculty of Medicine,
Department of Infectious Diseases and Clinical Microbiology, Istanbul Yeni Yu
Istanbul, Turkey
b
€ zy{l University Faculty of Medicine, Istanbul, Turkey
Department of Occupational Health and Safety, Istanbul Yeni Yu
c
€ zy{l University Faculty of Medicine, Istanbul, Turkey
Department of Infection Control Committee, Istanbul Yeni Yu
d
€ zy{l University Faculty of Medicine, Istanbul, Turkey
Department of Family Medicine, Istanbul Yeni Yu
e
€ zy{l University Faculty of Medicine, Istanbul, Turkey
Department of Chest Diseases, Istanbul Yeni Yu
f
€ zy{l University Faculty of Medicine, Istanbul, Turkey
Department of Pharmacology, Istanbul Yeni Yu
a
A R T I C L E
I N F O
A B S T R A C T
Article history:
Objectives: Comparative data on hydroxychloroquine and favipiravir, commonly used
Received 4 November 2021
agents in the treatment of Coronavirus Disease-2019 (COVID-19), are still limited. In this
Accepted 23 January 2022
study, it was aimed to compare treatment outcomes in healthcare workers with COVID-19
Available online xxx
who were prospectively followed by the occupational health and safety unit.
Methods: A total of 237 healthcare-workers, diagnosed as mild or moderate COVID-19
Keywords:
between March 11, 2020 and January 1, 2021, were given hydroxychloroquine (n = 114) or
SARS-CoV-2
favipiravir (n = 123). Clinical and laboratory findings were evaluated.
COVID-19
Results: The mean age of the patients was 33.4§11.5 years. The mean time to negative PCR
Hydroxychloroquine
was found to be significantly shorter in patients receiving favipiravir compared to the
Favipiravir
hydroxychloroquine group (10.9 vs. 13.9 days; p < 0.001). The rate of hospitalization in the
Healthcare workers
hydroxychloroquine group was significantly higher than favipiravir group (15.8% vs. 3.3%).
In terms of side effects; the frequency of diarrhea in patients receiving hydroxychloroquine
was significantly higher than that in the favipiravir group (31.6% vs. 6.5%; p < 0.001).
Conclusions: Favipiravir and hydroxychloroquine were similar in terms of improvement of
clinical symptoms of healthcare workers with mild or moderate COVID-19 infection, but
favipiravir was significantly more effective in reducing viral load and hospitalization rates.
Furthermore, favipiravir caused significantly less side-effects than hydroxychloroquine.
Ó 2022 Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Infectologia.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
€ zy{l University Fac* Corresponding author at: Istanbul Yeni Yu
Microbiology, Istanbul, Turkey.
ulty of Medicine, Department of Infectious Diseases and Clinical
E-mail address: deryabturan@gmail.com (D.B...
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit